

Tips to make documentation easier, faster, and more satisfying



Douglas Mossman, MD

CURRENT PSYCHIATRY'S malpractice column is evolving. Previously, "Malpractice Verdicts," used case decisions to initiate discussions of clinical situations that can generate lawsuits. The verdicts remain as "Malpractice Minute" (page 86), but CURRENT PSYCHIATRY has invited me to contribute a new column, "Malpractice Rx," that will solicit questions and address practicing clinicians' concerns about malpractice risk.

To start this dialogue, I'll begin with a question that often comes up in discussions with colleagues, and especially when I teach psychiatry residents: "What should I document?" In this article, we will review why proper documentation is essential. We'll also look at some ideas that might make documentation easier, more efficient, and more satisfying.

source—and often the only source—of information an attorney uses when deciding whether to file a lawsuit. An attorney won't risk time and money on a malpractice case if the clinical record suggests that a psychiatrist was conscientious and met the standard of care.¹

Impression management. The patient's chart is what plaintiffs' and defendants' experts use when forming their initial opinions about the quality of care delivered.

Credibility. Clinical records are the most believable source of information about what you observed, what you thought, what you did, why you did it, and when you did it. The adage "if it wasn't written, it didn't happen" is not always applicable,² but if an adverse event occurs,

Do you have a question about possible liability?

■ If so, please submit your malpractice-related questions to Dr. Mossman at douglas.mossman@dowdenhealth.com.

■ Include your name, address, and practice location. If your question is chosen for publication, your name can be withheld by request.

■ All readers who submit questions will be included in quarterly drawings for a \$50 gift certificate for Professional Risk Management Services, Inc's online marketplace of risk management publications and resources (www.prms.com).

Purposes of documentation

When I was in medical school, my professors said the primary reason for accurate charting was to communicate with the rest of the treatment team. This is still true. But in these sadder-but-wiser days, when I ask psychiatry residents "What is the purpose of documentation?" they always answer, "to create a legal record."

Documentation plays many roles (Table 1). From the standpoint of preventing a malpractice judgment, the clinical record can accomplish 3 important things:

Lawsuit deterrence. Records are a key

Table 1

Purposes of medical record documentation

- **Communicate** clinical information to current and future caregivers
- **Remind** you of what happened and what you did
- **Justify** care to third-party payers
- **Inform** professional standards review organizations
- **Satisfy** accrediting agencies
- **Create** a basis for defense in a malpractice action

Dr. Mossman is professor and director, division of forensic psychiatry, Wright State University Boonshoft School of Medicine, Dayton, OH, and administrative director, Glenn M. Weaver Institute of Law and Psychiatry, University of Cincinnati College of Law.

milk. Therefore, women should not breast-feed during treatment with RISPERDAL® CONSTA® and for at least 12 weeks after the last injection. **Pediatric Use:** RISPERDAL® CONSTA® has not been studied in children younger than 18 years old. **Geriatric Use:** In an open-label study, 57 clinically stable, elderly patients (≥65 years old) with schizophrenia or schizoaffective disorder received RISPERDAL® CONSTA® every 2 weeks for up to 12 months. In general, no differences in the tolerability of RISPERDAL® CONSTA® were observed between otherwise healthy elderly and nonelderly patients. Therefore, dosing recommendations for otherwise healthy elderly patients are the same as for nonelderly patients. Because elderly patients exhibit a greater tendency to orthostatic hypotension than nonelderly patients, elderly patients should be instructed in nonpharmacologic interventions that help to reduce the occurrence of orthostatic hypotension (e.g., sitting on the edge of the bed for several minutes before attempting to stand in the morning and slowly rising from a seated position). In addition, monitoring of orthostatic vital signs should be considered in elderly patients for whom orthostatic hypotension is of concern (see PRECAUTIONS, DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY in full PI). **Concomitant use with Furosemide in Elderly Patients with Dementia-Related Psychosis:** In placebo-controlled trials in elderly patients with dementia-related psychosis, a higher incidence of mortality was observed in patients treated with furosemide plus oral risperidone when compared to patients treated with oral risperidone alone or with oral placebo plus furosemide. No pathological mechanism has been identified to explain this finding, and no consistent pattern for cause of death was observed. An increase of mortality in elderly patients with dementia-related psychosis was seen with the use of oral risperidone regardless of concomitant use with furosemide. RISPERDAL® CONSTA® is not approved for the treatment of patients with dementia-related psychosis. (See **Boxed WARNING, WARNINGS: Increased Mortality in Elderly Patients with Dementia-Related Psychosis.**)

ADVERSE REACTIONS: Associated with Discontinuation of Treatment: In the 12-week, placebo-controlled trial, the incidence of schizophrenic patients who discontinued treatment due to an adverse event was lower with RISPERDAL® CONSTA® (11%; 22/202 patients) than with placebo (13%; 13/98 patients). **Incidence in Controlled Trials: Commonly Observed Adverse Events in Controlled Clinical Trials:** Spontaneously reported, treatment-emergent adverse events with an incidence of 5% or greater in at least one of the RISPERDAL® CONSTA® groups (25 mg or 50 mg) and at least twice that of placebo were: somnolence, akathisia, parkinsonism, dyspepsia, constipation, dry mouth, fatigue, weight increase. **Dose Dependency of Adverse Events: Extrapyramidal Symptoms:** The overall incidence of EPS-related adverse events (akathisia, dystonia, parkinsonism, and tremor) in patients treated with 25 mg RISPERDAL® CONSTA® was comparable to that of patients treated with placebo; the incidence of EPS-related adverse events was higher in patients treated with 50 mg RISPERDAL® CONSTA®. **Vital Sign Changes:** RISPERDAL® is associated with orthostatic hypotension and tachycardia (see PRECAUTIONS). In the placebo-controlled trial, orthostatic hypotension was observed in 2% of patients treated with 25 mg or 50 mg RISPERDAL® CONSTA® (see PRECAUTIONS). **Weight Changes:** In the 12-week, placebo-controlled trial, 9% of patients treated with RISPERDAL® CONSTA® compared with 6% of patients treated with placebo, experienced a weight gain of >7% of body weight at endpoint. **Laboratory Changes:** The percentage of patients treated with RISPERDAL® CONSTA® who experienced potentially important changes in routine serum chemistry, hematology, or urinalysis parameters was similar to or less than that of placebo patients. Additionally, no patients discontinued treatment due to changes in serum chemistry, hematology, or urinalysis parameters. **ECG Changes:** The electrocardiograms of 202 schizophrenic patients treated with 25 mg or 50 mg RISPERDAL® CONSTA® and 98 schizophrenic patients treated with placebo in a 12-week, double-blind, placebo-controlled trial were evaluated. Compared with placebo, there were no statistically significant differences in QTc intervals (using Fridericia's and linear correction factors) during treatment with RISPERDAL® CONSTA®. **Pain Assessment and Local Injection Site Reactions:** The mean intensity of injection pain reported by patients using a visual analog scale (0 = no pain to 100 = unbearably painful) decreased in all treatment groups from the first to the last injection (placebo: 16.7 to 12.6; 25 mg: 12.0 to 9.0; 50 mg: 18.2 to 11.8). After the sixth injection (Week 10), investigator ratings indicated that 1% of patients treated with 25 mg or 50 mg RISPERDAL® CONSTA® experienced redness, swelling, or induration at the injection site. **Other Events Observed During the Premarketing Evaluation of RISPERDAL® CONSTA®:** During its premarketing assessment, RISPERDAL® CONSTA® was administered to 1499 patients in multiple-dose studies. The conditions and duration of exposure to RISPERDAL® CONSTA® varied greatly, and included (in overlapping categories) open-label and double-blind studies, uncontrolled and controlled studies, inpatient and outpatient studies, fixed-dose and titration studies, and short-term and long-term exposure studies. The following reactions were reported: (Note: frequent adverse events are those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients. It is important to emphasize that, although the reported events occurred during treatment with RISPERDAL® CONSTA®, they were not necessarily caused by it.) **Psychiatric Disorders:** Frequent: anxiety, psychosis, depression, agitation, nervousness, paranoid reaction, delusion, apathy. Infrequent: anorexia, impaired concentration, impotence, emotional lability, manic reaction, decreased libido, increased appetite, amnesia, confusion, euphoria, depersonalization, paranoia, delirium, psychotic depression. **Central and Peripheral Nervous System Disorders:** Frequent: hypertonia, dystonia. Infrequent: dyskinesia, vertigo, leg cramps, tardive dyskinesia*, involuntary muscle contractions, paraesthesia, abnormal gait, bradykinesia, convulsions, hypokinesia, ataxia, fecal incontinence, oculogyric crisis, tetany, apraxia, dementia, migraine. Rare: neuroleptic malignant syndrome. *In the integrated database of multiple-dose studies (1499 patients with schizophrenia or schizoaffective disorder), 9 patients (0.6%) treated with RISPERDAL® CONSTA® (all dosages combined) experienced an adverse event of tardive dyskinesia. **Body as a Whole/General Disorders:** Frequent: back pain, chest pain, asthenia. Infrequent: malaise, choking. **Gastrointestinal Disorders:** Frequent: nausea, vomiting, abdominal pain. Infrequent: gastritis, gastroesophageal reflux, flatulence, hemorrhoids, melena, dysphagia, rectal hemorrhage, stomatitis, colitis, gastric ulcer, gingivitis, irritable bowel syndrome, ulcerative stomatitis. **Respiratory System Disorders:** Frequent: dyspnea. Infrequent: pneumonia, stridor, hemoptysis. Rare: pulmonary edema. **Skin and Appendage Disorders:** Frequent: rash. Infrequent: eczema, pruritus, erythematous rash, dermatitis, alopecia, seborrhea, photosensitivity reaction, increased sweating. **Metabolic and Nutritional Disorders:** Infrequent: hypercemia, hyperglycemia, hyperlipemia, hypokalemia, glycosuria, hypercholesterolemia, obesity, dehydration, diabetes mellitus, hyponatremia. **Musculo-Skeletal System Disorders:** Frequent: arthralgia, skeletal pain. Infrequent: torticollis, arthrosis, muscle weakness, tendinitis, arthritis, arthropathy. **Heart Rate and Rhythm Disorders:** Frequent: tachycardia. Infrequent: bradycardia, AV block, palpitation, bundle branch block. Rare: T-wave inversion. **Cardiovascular Disorders:** Frequent: hypotension. Infrequent: postural hypotension. **Urinary System Disorders:** Frequent: urinary incontinence. Infrequent: hematuria, micturition frequency, renal pain, urinary retention. **Vision Disorders:** Infrequent: conjunctivitis, eye pain, abnormal accommodation. **Reproductive Disorders, Female:** Frequent: amenorrhea. Infrequent: nonpuerperal lactation, vaginitis, dysmenorrhea, breast pain, leukorrhea. **Resistance Mechanism Disorders:** Infrequent: abscess. **Liver and Biliary System Disorders:** Frequent: increased hepatic enzymes. Infrequent: hepatomegaly, increased SGPT. Rare: bilirubinemia, increased GGT, hepatitis, hepatocellular damage, jaundice, fatty liver, increased SGOT. **Reproductive Disorders, Male:** Infrequent: ejaculation failure. **Application Site Disorders:** Frequent: injection site pain. Infrequent: injection site reaction. **Hearing and Vestibular Disorders:** Infrequent: earache, deafness, hearing decreased. **Red Blood Cell Disorders:** Frequent: anemia. **White Cell and Resistance Disorders:** Infrequent: lymphadenopathy, leucopenia, cervical lymphadenopathy. Rare: granulocytopenia, leukocytosis, lymphopenia. **Endocrine Disorders:** Infrequent: hyperprolactinemia, gynecostasia, hypothyroidism. **Platelet, Bleeding and Clotting Disorders:** Infrequent: purpura, epistaxis. Rare: pulmonary embolism, hematoma, thrombocytopenia. **Myo-, Endo-, and Pericardial and Valve Disorders:** Infrequent: myocardial ischemia, angina pectoris, myocardial infarction. **Vascular (Extracardiac) Disorders:** Infrequent: phlebitis. Rare: intermittent claudication, flushing, thrombophlebitis. **Postintroduction Reports:** Adverse events reported since market introduction which were temporally (but not necessarily causally) related to oral RISPERDAL® therapy include the following: anaphylactic reaction, angioedema, apnea, atrial fibrillation, cerebrovascular disorder, including cerebrovascular accident, diabetes mellitus aggravated, including diabetic ketoacidosis, hyperglycemia, intestinal obstruction, jaundice, mania, pancreatitis, Parkinson's disease aggravated, pituitary adenomas, pulmonary embolism, and QT prolongation. There have been rare reports of sudden death and/or cardiopulmonary arrest in patients receiving oral RISPERDAL®. A causal relationship with oral RISPERDAL® has not been established. It is important to note that sudden and unexpected death may occur in psychotic patients whether they remain untreated or whether they are treated with other antipsychotic drugs. Retinal artery occlusion after injection of RISPERDAL® CONSTA® has been reported during postmarketing surveillance. This has been reported in the presence of abnormal arteriovenous anastomosis.

DRUG ABUSE AND DEPENDENCE

Controlled Substance Class: RISPERDAL® CONSTA® (risperidone) is not a controlled substance.

For more information on symptoms and treatment of overdose, see full Prescribing Information.

7519510B - US Patent 4,804,663
2003

Revised September 2007

©Janssen



continued from page 80

a defendant doctor's verbal testimony about delivering good care will be more convincing when backed up by documentation created before the event.

Improving documentation

Because it is impossible to describe everything you see, hear, say, do, and think during clinical encounters with patients, you must make choices about what to include in the record. The components of good documentation depend on the clinical context, but the following general principles may avert some malpractice actions.

1 More is better. Psychiatric practice often requires you to be discreet about patients' personal information. Within appropriate bounds, however, the more information the record contains about objective findings, patients' statements, clinical judgments, and your decision making, the better the portrayal of competent care.

2 Record the time and date. When attorneys and experts try to reconstruct what happened before an adverse occurrence, knowing the exact time you saw the patient, recorded findings, wrote orders, followed up on lab tests, or discussed problems with others—including family and treatment team members—can make a big difference.

3 Sooner is better. The most credible charting is done during or just after a service is rendered. Charting completed after an adverse event is vulnerable to accusations of fabrication.

4 Describe your thinking. Most aspects of clinical medicine are far from certain. Documenting the reasoning behind your diagnosis and treatment selection—what you've ruled out, what still seems tentative, and what risks and benefits you've weighed—helps emphasize this reality.³ After some-

Table 2

6 more ideas about improving your documentation

Idea	Comment
Use speech recognition software	You speak faster than you write. Transcription software accuracy has improved in the last few years.
Use handouts and medication instructions	Patients often do not remember or understand much of what doctors tell them, ^{7,8} so handouts may be more useful than verbal instructions. Good handouts about medications are available on the Internet. Note in the chart that you gave the patient the document.
Seek anonymous consultations with colleagues	Documenting consultations shows you are prudent and a colleague agreed with your treatment.
Ask patients to rate their own symptoms and progress	This practice may improve your information gathering and help document what the patient told you.
Use standard rating scales	Rating scales can help you record more information in a scientifically validated format.
Use macros and templates	Macros can reduce time needed for documentation. Your memory isn't perfect, but templates can help you include everything you need to cover.

thing bad happens, people retrospectively regard the event as more probable than it really was.⁴ Documenting your uncertainty and ways of addressing it may help counter this "hindsight bias." It also shows that you were thoughtful and took therapeutic steps prudently.

5 Collaborate with the patient. In some circumstances, it is appropriate to draft documents in a patient's presence. Examples might include information sent to third-party payers or referrals to other clinicians. Noting that you've done this demonstrates the patient's awareness and implicit concurrence. Also, collaborative documentation reinforces the "working together" aspects of a doctor-patient relationship and can be therapeutic.⁵

6 Clarify capacity. Jurors may believe that all psychiatric patients are incompetent, and plaintiff's attorneys sometimes try to create the impression that patients are completely controlled by weird whims and aberrant thoughts. To counter this, when appropriate indicate in the chart that the patient can handle responsibilities such as

reporting side effects, seeking emergency attention, or notifying you about changes in thought or mood.^{3,5}

7 Manage appearance and content. Under Health Insurance Portability and Accountability Act (HIPAA) regulations, patients have the right to review their medical records.⁶ If a lawsuit occurs, the records might be read out loud in court. Documentation will make a better impression if it is clear, legible, and free of gratuitous comments.

8 Include quotations. Documenting verbatim statements from a patient, such as "I've never considered suicide," can quickly convey key information that you considered when making a therapeutic decision.

Technical approaches

Table 2^{7,8} lists several techniques and technologies that might improve documentation. For example, computer users can create templates or customize software to quickly produce thorough documentation for frequently encountered procedures or

Clinical Point

Good documentation depends on the clinical context, but following some general principles may avert successful malpractice actions

Malpractice minute



We give you facts of an actual malpractice case. Submit your verdict at CurrentPsychiatry.com and see how your colleagues voted.

Was the patient still suicidal?

THE PATIENT. A 30-year-old police officer reports thoughts of suicide. He was under investigation for illegal work-related activities and feared he would have to report his coworkers' involvement in these activities and lose his job.

CASE FACTS. The patient was voluntarily hospitalized for 4 days and received medication and inpatient psychotherapy. When he was discharged, a psychiatrist prescribed follow-up outpatient psychotherapy and antidepressant and antipsychotic medications. The next day, the officer fatally shot himself.

THE PATIENT'S FAMILY'S CLAIM. The psychiatrist did not adequately weigh the patient's depression and stressors, including possibly losing his job, and did not properly assess suicidal ideation. Also, the patient's mother claims she attended the discharge meeting with the psychiatrist and that her son expressed suicidal intentions at that time.

THE DOCTOR'S DEFENSE. The patient believed he could get another job if necessary and was no longer contemplating suicide. Also, he was a voluntary patient and could not be hospitalized any longer without consent.

YOUR VERDICT LIABLE NOT LIABLE

Submit your verdict and find out how the court ruled at CurrentPsychiatry.com. Click on "Have more to say about this topic?" to comment.

Cases are selected by CURRENT PSYCHIATRY from *Medical Malpractice Verdicts, Settlements & Experts*, with permission of its editor, Lewis Laska of Nashville, TN (www.verdictslaska.com). Information may be incomplete in some instances, but these cases represent clinical situations that typically result in litigation.



clinical events. Whether these approaches are useful and appropriate will depend on your work setting, but all aim to improve the speed and quality of clinical documentation.

Think creatively about improving documentation. Even if you're never sued, better documentation helps you and your patients. For example, several years ago a colleague⁹ designed an emergency room form that allowed clinicians to complete in a few seconds a Brief Psychiatric Rating Scale on every patient we evaluated. This innovation shortened the time needed to document a systematic, comprehensive assessment and increased the quantity, quality, and reliability of information in patients' records.

References

1. Simpson S, Stacy M. Avoiding the malpractice snare: documenting suicide risk assessment. *J Psychiatr Pract* 2004;10:185-9.
2. Zurad EG. Don't be the target of a malpractice suit. *Fam Pract Manag* 2006;13(6):57-64.
3. Gutheil TG. Fundamentals of medical record documentation. *Psychiatry* 2004;1:26-8.
4. Fischhoff B, Beyth R. "I knew it would happen": remembered probabilities of once-future things. *Organ Behav Hum Perform* 1975;13:1-16.
5. Appelbaum PS, Gutheil TG. *Clinical handbook of psychiatry and the law*. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2007.
6. 45 CFR § 164.524(a)(1).
7. Rogers AE, Addington-Hall JM, Abery AJ, et al. Knowledge and communication difficulties for patients with chronic heart failure: qualitative study. *BMJ* 2000;321:605-7.
8. Chesnow N. Are you getting through? *Med Econ* 2006;83(13):41,45-6.
9. Somoza E, Somoza JR. A neural-network approach to predicting admission decisions in a psychiatric emergency room. *Med Decis Making* 1993;13:273-80.